Mercury Toxicity Following Unauthorized Siddha Medicine Intake - A Mimicker of Acquired Neuromyotonia - Report of 32 Cases
- PMID: 29720798
- PMCID: PMC5909146
- DOI: 10.4103/aian.AIAN_274_17
Mercury Toxicity Following Unauthorized Siddha Medicine Intake - A Mimicker of Acquired Neuromyotonia - Report of 32 Cases
Abstract
Context: Mercury is used extensively in the preparation of Siddha medicines, after purification. In this study, we present 32 patients of mercury toxicity following unauthorized Siddha medicine intake who mimicked neuromyotonia clinically. We analyzed the clinical features of these patients, the role of autoimmunity in etiopathology, and compared it with acquired neuromyotonia.
Subjects and methods: This is a retrospective study to analyze inpatients in a tertiary care center, admitted with mercury toxicity following Siddha medicine intake from August 2012 to October 2016. We analyzed the clinical features, laboratory data including mercury, arsenic and lead levels in blood, and serum voltage-gated potassium channels (VGKC)-CASPR2 Ab in selected patients.
Results: Thirty-two patients who had high blood mercury levels following Siddha medicine intake were included in the study. All patients (100%) had severe intractable neuropathic pain predominantly involving lower limbs. Twenty-six (81.25%) patients had fasciculations and myokymia. Fifteen patients (46.86%) had autonomic dysfunction (postural hypotension and resting tachycardia). Nine (28.12%) patients had encephalopathic features such as dullness, apathy, drowsiness, or delirium. Anti-VGKC Ab was positive in 12 patients with myokymia. All the patients in the study consumed Siddha medicines obtained from unauthorized dealers.
Conclusions: Mercury toxicity following Siddha medicine intake closely mimics acquired neuromyotonia; severe intolerable neuropathic pain is the hallmark feature; Positive VGKC-CASPR2 antibody in some patients must be due to triggered autoimmunity secondary to mercury toxicity due to Siddha medicine intake. The government should establish licensing system to prevent distribution of unauthorized Siddha medicines.
Keywords: Mercury toxicity; Siddha medicine toxicity; myokymia; neuromyotonia; voltage gated potassium channels-CASPR2 Ab.
Conflict of interest statement
There are no conflicts of interest.
Figures
References
-
- Sharma PV. Siddha medicine. In: Sharma PV, editor. History of Medicine in India. New Delhi: The Indian National Science Academy; 1992. pp. 445–50.
-
- Subbarayappa BV. Chemical practices and alchemy. In: Bose DM, Sen SN, Subbarayappa BV, editors. A Concise History of Science in India. New Delhi: Indian National Science Academy; 1971. pp. 315–35.
-
- “Rasa Shastra – Freedom Vidya”. [Last accessed on 2017 Jul 15]. Available from: http://www.Shrifreedom.org .
-
- Medicinal Preparations. [Last accessed on 2017 Jul 15]. Available from: http://www.siddha-medicine.org/index.html .
